Genaissance launches gene test for heart defects:
This article was originally published in Clinica
Genaissance Pharmaceuticals has launched a pharmacogenomic test for cardiac channelopathies - a broad clinical category that includes Long QT and Brugada Syndromes, two causes of arrhythmia that can result in sudden cardiac death. The CLIA-compliant test can confirm the presence of mutations known to cause cardiac channelopathies; identify family members who have similar mutations; and assist physicians in choosing the most appropriate course of treatment for each patient. It works by detecting genetic mutations in five cardiac ion channel genes. It is expected to provide an improvement to cardiac channelopathies testing using traditional electrocardiograms, which may miss a diagnosis, leaving a patient at risk of a sudden cardiac death, said the New Haven, Connecticut firm.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.